Skip to content

Safety and efficiency of human umbilical cord mesenchymal stem cells in the treatment of CSF1R-microglial encephalopathy: a clinical research

Safety and efficiency of human umbilical cord mesenchymal stem cells in the treatment of CSF1R-microglial encephalopathy: a clinical research

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053114
Enrollment
Unknown
Registered
2021-11-12
Start date
2021-11-10
Completion date
Unknown
Last updated
2022-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CSF1R microglial encephalopathy

Interventions

Experimental group:Stem cells for research

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria of CSF1R microglial encephalopathy (appendix II); 2.Have a genetic diagnosis confirming the presence of a CSF1R gene mutation; 3.Aged 18 to 60 years, regardless of gender; 4.Duration of disease > 2 years; persistent exacerbation of symptoms and no contraindications to treatment; 5.Able to guarantee completion of the full research project of this study and able to cooperate with the physician in treatment and follow-up; 6.Have not received stem cell transplantation within the last 6 months; 7.Have not participated in any clinical trial studies within the last 3 months; 8.Consent to stem cell therapy and voluntarily sign an informed consent form; 9.Be treated with umbilical cord MSCs and sign the informed consent form in person or by a relative.

Exclusion criteria

Exclusion criteria: 1.Severe dyslexia, severe audio-visual impairment, etc., which prevents completion of cognitive function assessments; 2.Combined contraindications to magnetic resonance imaging, such as claustrophobia, pacemakers, metal implants, etc. 3.Combination of severe heart, lung, liver, kidney, malignancy, haematological disorders and other brain disorders with unstable vital signs; 4.Patients who have participated in other drug clinical trials or are participating in other clinical trials within 3 months prior to screening; 5.Patients who, in the opinion of the investigator, are not suitable to participate in this trial.

Design outcomes

Primary

MeasureTime frame
activities of daily living;motor function;

Secondary

MeasureTime frame
cognition function;high signal volume in white matter;mental behavior;annual recurrence rate;

Countries

China

Contacts

Public ContactXu Jun

Beijing Tiantan Hospital, Capital Medical University

neurojun@126.com+86 13581569328

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026